Industry News
Pharmaceutical Industry News
Sun Pharma will acquire Organon…
Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. BeOne Medicines is joining the PD-1xVEGF race with an option for a trispecific antibody. And more.
Looking to clarify its…
Looking to clarify its expectations for manufacturer responses following inspections, the FDA earlier this year unveiled, for the first time, draft guidance on best practices for the industry when replying to the receipt of a
As Eli Lilly gets off to the races…
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared
Bristol Myers Squibb’s growth…
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition.
While Merck’s PAH treatment…
While Merck's PAH treatment Winrevair continued its upward trajectory, another of its growth products, COPD medicine Ohtuvayre, took a step back in the first quarter.
Amarox, the U.K. unit of India’s…
Amarox, the U.K. unit of India’s Hetero Group, issued a voluntary recall of one batch of sertraline tablets in Britain after a patient found two different antidepressants packaged together.
Rising Stars: A strategic…
Rising Stars: A strategic marketing lead at CDMO Axplora, Arsalan Khan is also a chemical and pharmaceutical engineer, a published author and an avid tennis player.
The FDA has reprimanded Bayer for…
The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s prostate cancer drug Nubeqa.
Merck is making its pitch that…
Merck is making its pitch that high levels of so-called “bad cholesterol” can increase the risk of heart attack or stroke with its new “Playing with Heart” project.
The European Medicines Agency…
The European Medicines Agency (EMA) has launched an advisory group designed to help boost “vaccine confidence” amid growing hesitancy in the region.
Novartis will construct an active…
Novartis will construct an active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, the company said Thursday. The 56,200 square-foot plant will manufacture compounds for solid-dose tablets, capsules and RNA therapeutics.
As AstraZeneca braces for the…
As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a “very conservative” way to model the fallout would be removing the eight reference markets
While Teva Pharmaceutical’s…
While Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis showed signs of leveling off, the company still topped Wall Street estimates in 2026’s first quarter, buoyed by the impressive performance of branded drugs like
Immunology med Skyrizi charted…
Immunology med Skyrizi charted sales growth of 30.9% over 2026's first quarter, bringing in $4.48 billion as AbbVie's top earner.
As regulatory delays continue to…
As regulatory delays continue to plague Regeneron's Eylea franchise, quarterly sales for the eye disease medicine have dropped below $1 billion for the first time since the second quarter of 2018.
In GSK’s first quarter with Luke…
In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales record while its closely watched asthma launch Exdensur showed “early signals” of commercial progress despite
As Ekterly nears the one-year…
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.
Patient groups’ perceptions of…
Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have contended with political pressures, PatientView said.
With a new positive trial readout,…
With a new positive trial readout, the company is aiming to reach a broader set of patients with its multiple myeloma bispecific Elrexfio.
Novartis CEO Vas Narasimhan says…
Novartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on how it prices its drugs, warning that the entrance of new pharmaceuticals into its markets could be delayed.